CI

At a glance

ClinicalIndex Comparison Record
N/AActive· 67 enrolled
Drug / intervention
Oral Sodium Chloride +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04334668
NCT04334668N/AActive

Oral Sodium to Preserve Renal EfficiencY in Acute Heart Failure (OSPREY-AHF)

The Cleveland Clinic·interventional·Posted Apr 6, 2020·Updated Feb 20, 2026

In Brief

A clinical study evaluating Oral Sodium Chloride and Placebo for Volume Overload. Active but no longer recruiting, targeting 67 participants across 1 site.

Detailed Summary

The investigators are proposing a prospective, randomized, double blinded, placebo-controlled single center study evaluating the role of co-administration of oral sodium chloride (NaCl) with intravenous diuretics in patients hospitalized with acute decompensated heart failure. The investigators are approaching this study with the hypothesis that the use of oral sodium chloride leads to improved effective diuresis (as measured by weight loss) and renal function as compared to placebo in patients hospitalized with acute decompensated heart failure undergoing aggressive intravenous diuretic therapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVolume Overload
CountriesUnited States
Collaborators--

Timeline

N/AActive
2021202220232024202520262027
First PostedApr 6, 2020
Enrollment StartMay 20, 2020
Primary CompletionJun 1, 2022
Study CompletionDec 31, 2026
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 6.2 years ago

Interventions

Oral Sodium Chloridedietary

Subjects will be randomized to receive 2 grams oral Sodium Chloride three times daily with meals for approximately 4 days

Placeboother

Subjects will be randomized to receive a placebo three times daily with meals for approximately 4 days.